Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Next Previous
Trial Profile

A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MaaT 033 (Primary)
  • Indications Haematological malignancies; Transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms PHOEBUS
  • Sponsors MaaT Pharma

Most Recent Events

  • 19 Jun 2025 According to a MaaT Pharma media release, last patient enrollment in this study is expected in mid-2026, and the 1-year OS results are expected in H2 2027.
  • 13 Jun 2025 According to a MaaT Pharma media release, company presented trial design data from this study in a poster presentation at the European Hematology Association (EHA) Annual Congress 2025.
  • 14 May 2025 According to a MaaT Pharma media release, the company announced that a poster of trial design has been selected to present at the European Hematology Association (EHA) Annual congress, taking place in Milan from June 12-15, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top